n item 4, we recommend to oppose the re-appointment of the Chairman-CEO Mr. Huertas Mejías, we have serious concerns over the excessive concentration of powers, also taking into account the lack of independent representation on the Board (40%).
In item 8, the Board proposes to amend the Regulations of the General Meeting by eliminating the power to approve the issue of non-convertible bonds. In our opinion, a mandatory shareholders' approval may prevent companies from excessive use, or any abuses, of debt instruments. Hence, we recommend opposition.
In items 9 and 10, we recommend to oppose the authorization to respectively issue convertible securities and to increase the share capital, because the maximum amount of shares to be issued without pre-emptive rights (up to 20% of the share capital) exceeds our voting policy limit (10%).
In item 11, the Board proposes to change the remuneration policy approved in 2016, by introducing the payment of attendance fees to the members of Board Committees. Pursuant to Spanish legislation, any changes to the 3-year remuneration policy shall be subject to a binding shareholders' approval. Although we agree that part of the non-executive Directors' compensation is linked to real attendance of meetings, we regret that no changes are proposed to the remuneration policy for executive Directors, despite the very high level of dissent of minority shareholders in 2016 (71.6% of against votes, excluding the shares of the controlling shareholder Fundación Mapfre). In particular, we regret that the Company has not disclosed the individual maximum amount of each variable remuneration component (on aggregate, the variable components are capped at 150% of the base salary in any year) and all relevant performance conditions. Furthermore, pension contributions are excessive (above 200% of the CEO's fixed remuneration in the last 3 years) and serious concerns may arise over the discretionary power of the Board in awarding severance payments, which are not included in the executive contract. Therefore, we recommend opposition. For the same reasons, we also recommend to oppose the Annual Remuneration Report (item 12 – advisory vote).
Mapfre is an insurance company based in Spain. Co. is the parent company of a group engaged in the underwriting and provision of insurance in Spain and abroad. Insurance policies provided include: life, non-life, accident, home-owner, general and health. Through its subsidiaries, Co. is also engaged in the provision of reinsurance, the management of investment funds, pension funds and pension plans, real estate and related services. On the domestic market, Co.'s activities include managing investment funds, pension funds and pension plans, real estate and other service businesses.
Founded in 1995, Proxinvest is an independent proxy firm supporting the engagement and proxy analysis processes of investors. Proxinvest mission is to analyse corporate governance practices and resolutions proposed at general meetings of listed firms.
Proxinvest main services are :
Proxinvest has been a pioneer and champion of good corporate governance and has grown into a recognised expert in the field.
Proxinvest is independently-owned and only works for investors : Proxinvest does not provide consulting services to the companies it covers, mitigating related risks to its clients and ensuring the independence of our analysis. As a result Proxinvest is able to take a robust, independent, engaged and unconflicted view of the companies in which our clients invest.
As Managing Partner of Expert Corprate Governance Service Ltd (ECGS), Proxinvest has built a large network of corporate governance experts to support clients in corporate governance analysis worldwide.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.